Edap Tms (NASDAQ:EDAP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Friday.
According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “
EDAP has been the subject of several other reports. ValuEngine upgraded shares of Edap Tms from a “sell” rating to a “hold” rating in a research note on Friday, October 6th. HC Wainwright reiterated a “buy” rating and issued a $6.50 target price on shares of Edap Tms in a research note on Monday, October 9th.
Edap Tms (NASDAQ:EDAP) last posted its earnings results on Wednesday, November 15th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). Edap Tms had a negative net margin of 5.36% and a positive return on equity of 7.85%. The firm had revenue of $8.44 million during the quarter, compared to analysts’ expectations of $11.05 million. Edap Tms’s quarterly revenue was down 5.6% on a year-over-year basis. analysts forecast that Edap Tms will post -0.01 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of EDAP. Archon Capital Management LLC increased its holdings in Edap Tms by 12.5% in the 3rd quarter. Archon Capital Management LLC now owns 843,489 shares of the medical equipment provider’s stock worth $2,514,000 after acquiring an additional 93,762 shares in the last quarter. Essex Investment Management Co. LLC increased its holdings in Edap Tms by 520.2% in the 3rd quarter. Essex Investment Management Co. LLC now owns 323,528 shares of the medical equipment provider’s stock worth $964,000 after acquiring an additional 271,367 shares in the last quarter. Finally, Virtu KCG Holdings LLC purchased a new stake in Edap Tms in the 2nd quarter worth $117,000. Hedge funds and other institutional investors own 10.34% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Lowers Edap Tms (EDAP) to Hold” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2018/01/19/zacks-investment-research-lowers-edap-tms-edap-to-hold.html.
Edap Tms Company Profile
EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.